Annual CFF
$100.00 K
+$16.00 K+19.05%
31 December 2023
Summary:
Y-mAbs Therapeutics annual cash flow from financing activities is currently $100.00 thousand, with the most recent change of +$16.00 thousand (+19.05%) on 31 December 2023. During the last 3 years, it has fallen by -$1.90 million (-95.01%). YMAB annual CFF is now -99.93% below its all-time high of $134.70 million, reached on 31 December 2019.YMAB Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$979.00 K
-$779.00 K-44.31%
30 September 2024
Summary:
Y-mAbs Therapeutics quarterly cash flow from financing activities is currently $979.00 thousand, with the most recent change of -$779.00 thousand (-44.31%) on 30 September 2024. Over the past year, it has increased by +$979.00 thousand (+100.00%). YMAB quarterly CFF is now -99.27% below its all-time high of $134.70 million, reached on 31 December 2019.YMAB Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$3.42 M
+$979.00 K+40.02%
30 September 2024
Summary:
Y-mAbs Therapeutics TTM cash flow from financing activities is currently $3.42 million, with the most recent change of +$979.00 thousand (+40.02%) on 30 September 2024. Over the past year, it has increased by +$3.42 million (+100.00%). YMAB TTM CFF is now -97.47% below its all-time high of $135.29 million, reached on 30 September 2020.YMAB TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
YMAB Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +19.1% | +100.0% | +100.0% |
| 3 y3 years | -95.0% | +294.8% | -96.9% |
| 5 y5 years | -99.9% | +100.0% | +285.9% |
YMAB Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -99.9% | +19.1% | -44.3% | -96.9% | ||
| 5 y | 5 years | -99.9% | +19.1% | -99.3% | -97.5% | +285.9% | |
| alltime | all time | -99.9% | +19.1% | -99.3% | +153.2% | -97.5% | +285.9% |
Y-mAbs Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $979.00 K(-44.3%) | $3.42 M(+40.0%) |
| June 2024 | - | $1.76 M(+199.0%) | $2.45 M(+255.5%) |
| Mar 2024 | - | $588.00 K(+488.0%) | $688.00 K(+588.0%) |
| Dec 2023 | $100.00 K(+19.0%) | $100.00 K(>+9900.0%) | $100.00 K(>+9900.0%) |
| Sept 2023 | - | $0.00(0.0%) | $0.00(-100.0%) |
| June 2023 | - | $0.00(0.0%) | $52.00 K(0.0%) |
| Mar 2023 | - | $0.00(0.0%) | $52.00 K(-38.1%) |
| Dec 2022 | $84.00 K(-99.9%) | $0.00(-100.0%) | $84.00 K(-54.3%) |
| Sept 2022 | - | $52.00 K(>+9900.0%) | $184.00 K(-51.6%) |
| June 2022 | - | $0.00(-100.0%) | $380.00 K(-25.6%) |
| Mar 2022 | - | $32.00 K(-68.0%) | $511.00 K(-99.5%) |
| Dec 2021 | $108.31 M | $100.00 K(-59.7%) | $108.31 M(-1.2%) |
| Sept 2021 | - | $248.00 K(+89.3%) | $109.63 M(+0.0%) |
| June 2021 | - | $131.00 K(-99.9%) | $109.60 M(+0.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | $107.83 M(+7499.4%) | $109.47 M(+5362.5%) |
| Dec 2020 | $2.00 M(-98.5%) | $1.42 M(+560.0%) | $2.00 M(-98.5%) |
| Sept 2020 | - | $215.00 K(>+9900.0%) | $135.29 M(+0.2%) |
| June 2020 | - | $0.00(-100.0%) | $135.07 M(0.0%) |
| Mar 2020 | - | $370.00 K(-99.7%) | $135.07 M(+0.3%) |
| Dec 2019 | $134.70 M(+36.4%) | $134.70 M(>+9900.0%) | $134.70 M(-7412.9%) |
| Sept 2019 | - | $0.00(0.0%) | -$1.84 M(-101.8%) |
| June 2019 | - | $0.00(0.0%) | $100.53 M(+0.1%) |
| Mar 2019 | - | $0.00(-100.0%) | $100.40 M(+1.7%) |
| Dec 2018 | $98.76 M(+10.2%) | -$1.84 M(-101.8%) | $98.76 M(-1.8%) |
| Sept 2018 | - | $102.37 M(<-9900.0%) | $100.61 M(-5790.3%) |
| June 2018 | - | -$127.00 K(-92.3%) | -$1.77 M(+7.7%) |
| Mar 2018 | - | -$1.64 M | -$1.64 M |
| Dec 2017 | $89.59 M(+372.2%) | - | - |
| Dec 2016 | $18.97 M | - | - |
FAQ
- What is Y-mAbs Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics annual CFF year-on-year change?
- What is Y-mAbs Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics quarterly CFF year-on-year change?
- What is Y-mAbs Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics TTM CFF year-on-year change?
What is Y-mAbs Therapeutics annual cash flow from financing activities?
The current annual CFF of YMAB is $100.00 K
What is the all time high annual CFF for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high annual cash flow from financing activities is $134.70 M
What is Y-mAbs Therapeutics annual CFF year-on-year change?
Over the past year, YMAB annual cash flow from financing activities has changed by +$16.00 K (+19.05%)
What is Y-mAbs Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of YMAB is $979.00 K
What is the all time high quarterly CFF for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high quarterly cash flow from financing activities is $134.70 M
What is Y-mAbs Therapeutics quarterly CFF year-on-year change?
Over the past year, YMAB quarterly cash flow from financing activities has changed by +$979.00 K (+100.00%)
What is Y-mAbs Therapeutics TTM cash flow from financing activities?
The current TTM CFF of YMAB is $3.42 M
What is the all time high TTM CFF for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high TTM cash flow from financing activities is $135.29 M
What is Y-mAbs Therapeutics TTM CFF year-on-year change?
Over the past year, YMAB TTM cash flow from financing activities has changed by +$3.42 M (+100.00%)